BELLUS Health (BLU) Stock Forecast, Price Target & Predictions
BLU Stock Forecast
BELLUS Health stock forecast is as follows: an average price target of $14.75 (represents a 0.07% upside from BLU’s last price of $14.74) and a rating consensus of 'Hold', based on 1 wall street analysts offering a 1-year stock forecast.
BLU Price Target
The average price target for BELLUS Health (BLU) is $14.75 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $14.75 to $14.75. This represents a potential 0.07% upside from BLU's last price of $14.74.
BLU Analyst Ratings
According to 1 Wall Street analysts, BELLUS Health's rating consensus is 'Hold'. The analyst rating breakdown for BLU stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 1 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
BELLUS Health Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 18, 2023 | Sector Perform | RBC Capital | $14.75 | $14.44 | 2.15% | 0.07% |
The latest BELLUS Health stock forecast, released on Apr 18, 2023 by Sector Perform from RBC Capital, set a price target of $14.75, which represents a 2.15% increase from the stock price at the time of the forecast ($14.44), and a 0.07% increase from BLU last price ($14.74).
BELLUS Health Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $14.74 | $14.74 | $14.74 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of BELLUS Health stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to BELLUS Health's last price of $14.74. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Apr 18, 2023 | RBC Capital | Outperform | Sector Perform | Downgrade |
| Jul 13, 2022 | RBC Capital | Outperform | Outperform | Hold |
BELLUS Health's last stock rating was published by RBC Capital on Apr 18, 2023. The company Downgrade its BLU rating from "Outperform" to "Sector Perform".
BELLUS Health Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals | $0.37 | $3.67 | 891.89% | Buy |
| GOSS | Gossamer Bio | $0.71 | $3.75 | 428.17% | Buy |
| INZY | Inozyme Pharma | $2.81 | $14.67 | 422.06% | Buy |
| BMEA | Biomea Fusion | $6.42 | $22.75 | 254.36% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.39 | $7.00 | 192.89% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| STOK | Stoke Therapeutics | $11.61 | $30.60 | 163.57% | Buy |
| KALV | KalVista Pharmaceuticals | $9.05 | $22.67 | 150.50% | Buy |
| TERN | Terns Pharmaceuticals | $5.91 | $14.25 | 141.12% | Buy |
| VRDN | Viridian Therapeutics | $20.24 | $37.92 | 87.35% | Buy |
| CYTK | Cytokinetics | $51.09 | $83.23 | 62.91% | Buy |
| KURA | Kura Oncology | $15.96 | $26.00 | 62.91% | Buy |
| AKRO | Akero Therapeutics | $31.03 | $46.00 | 48.24% | Buy |
| DYN | Dyne Therapeutics | $29.68 | $43.88 | 47.84% | Buy |
| EWTX | Edgewise Therapeutics | $31.51 | $45.00 | 42.81% | Buy |
| AMLX | Amylyx Pharmaceuticals | $5.22 | $6.67 | 27.78% | Buy |
| CRNX | Crinetics Pharmaceuticals | $55.17 | $70.14 | 27.13% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| BLU | BELLUS Health | $14.75 | $14.75 | - | Hold |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |